StreetInsider.com News Articles

Rodman & Renshaw Starts Eledon Pharamceuticals (ELDN) at Buy

Tue, 21 Jul 2026 06:31:07 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharamceuticals (NASDAQ: ELDN) with a Buy rating and a price target of $12.00.

The analyst comments "We are initiating coverage of Eledon (ELDN) with a BUY rating and $12 price target, implying ~200% upside from current levels. Eledon is developing tegoprubart, an anti-CD40L antibody aiming to replace calcineurin inhibitor (CNI) based immunosuppression in transplant settings. The lead indication is de novo kidney transplantation, with Ph3 expected to start by the end of this year, and topline data anticipated ~2H29. A second value driver is islet-cell transplantation for type 1 diabetes, which

Rodman & Renshaw Starts Eledon Pharamceuticals (ELDN) at Buy

Tue, 21 Jul 2026 06:31:07 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharamceuticals (NASDAQ: ELDN) with a Buy rating and a price target of $12.00.

NewcelX gets FDA feedback supporting NCEL-101 diabetes trial path

Wed, 01 Jul 2026 09:30:17 -0400

NewcelX Ltd. (Nasdaq: NCEL) announced it has completed a Type B Pre-IND meeting with the U.S. Food and Drug Administration, receiving feedback that supports the company's proposed development strategy for NCEL-101, its stem cell-derived islet product candidate for type 1 diabetes.

The FDA provided favorable feedback on NewcelX's Chemistry, Manufacturing, and Controls processes and preclinical program, allowing the company to proceed toward Investigational New Drug enabling activities. The planned clinical trial would combine NCEL-101 with tegoprubart, an investigational anti-CD40L antibody developed by Eledon Pharmaceuticals (Nasdaq: ELDN).

Ronen Twito, CEO and Executive Chairman of NewcelX, said: "Coming out of our FDA meeting, we

NewcelX gets FDA feedback supporting NCEL-101 diabetes trial path

Wed, 01 Jul 2026 09:30:17 -0400

Ronen Twito, CEO and Executive Chairman of NewcelX, said: "Coming out of our FDA meeting, we

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

Wed, 01 Jul 2026 09:30:00 -0400

FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart

ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration (“FDA”). The agency provided constructive feedback and alignment on the Company’s proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (Nasdaq: ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

Wed, 01 Jul 2026 09:30:00 -0400

FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart

Natera and Eledon partner on kidney transplant Phase 3 trial